Ezdinli E Z, Simonson K L, Simonson L G, Wasser L P
Cancer. 1979 Jul;44(1):106-11. doi: 10.1002/1097-0142(197907)44:1<106::aid-cncr2820440119>3.0.co;2-7.
We report the presence of a rosette inhibiting factor (RIF) in the plasma of patients with active Hodgkin's disease. This factor suppresses the rosette forming ability of autologous Active T, Total T, and B lymphocytes with sheep red blood cells, and tends to disappear when clinical remission is achieved. To a lesser extent, the RIF also lowers the Active T, Total T and B-RFC percentages of lymphocytes obtained from normal donors. Although carcinoma and non-Hodgkin's lymphoma patients, as a group, did not exhibit rosette inhibitive properties, certain individuals with these diagnoses did show isolated RIF activity. The RIF could be adsorbed out of plasma using peripheral blood lymphocytes (PBL) from normal controls and appears to be a large heat stable molecule which does not affect PBL viability.
我们报告了在活动性霍奇金病患者血浆中存在一种玫瑰花结抑制因子（RIF）。该因子可抑制自体活性T细胞、总T细胞和B淋巴细胞与绵羊红细胞形成玫瑰花结的能力，并且在临床缓解时往往会消失。在较小程度上，RIF也会降低从正常供体获得的淋巴细胞的活性T细胞、总T细胞和B淋巴细胞玫瑰花结形成细胞（B-RFC）百分比。尽管癌症和非霍奇金淋巴瘤患者作为一个群体未表现出玫瑰花结抑制特性，但某些患有这些疾病的个体确实表现出单独的RIF活性。使用来自正常对照的外周血淋巴细胞（PBL）可从血浆中吸附出RIF，并且它似乎是一种对PBL活力无影响的大型热稳定分子。
